|
Fazal R. Khan, Ph.D. joined Merrimack Pharmaceuticals in April 2006 as the Vice President of Manufacturing. Most recently, Dr. Khan worked at Cellective Therapeutics, Inc. as Vice President of Manufacturing, until the company was acquired by MedImmune. Prior to Cellective, Dr. Khan was Vice President of Manufacturing Operations at Human Genome Sciences (HGS). Preceding his work at HGS, Dr. Khan was the Director of Biopharmaceuticals Development and Manufacturing at Hoffmann-LaRoche, Inc. During his tenure at Hoffmann-LaRoche, Dr. Khan managed the development and manufacturing of several biologics for clinical trials and for commercial needs. Dr. Khan gained international experience working with Roche Basel in Switzerland, Celltech Group in the United Kingdom and Nippon Roche in Japan. Dr. Khan received his B.S. in Biology and M.S. and PhD in Biochemistry from Aligarh University in India. | 